Aevi Genomic Medicine Inc. completed its private placement of common shares and warrants for proceeds of $28 million, before expenses.

The Children's Hospital of Philadelphia Foundation was the lead investor.

Aevi Genomic plans to use net proceeds for the development of its two lead clinical programs and other product candidates, to support its collaboration with Children's Hospital of Philadelphia, and for general corporate purposes.

Jefferies LLC served as financial adviser to Aevi Genomic for the transaction and Evercore LLC served as financial adviser to the Children's Hospital of Philadelphia Foundation.